Category Archives: Uncategorized

Does multi-district litigation violate the due-process rights of plaintiffs swept into it?

Law professor Martin Redish and law student Jullie Karaba think so, as they explain in One Size Doesn't Fit All: Multidistrict Litigation, Due Process, and the Dangers of Procedural Collectivism. Here is the abstract: Panel of federal judges regularly transfers cases which may share no more than one common issue from federal districts all over […]

Judge refuses Apple’s request to seal documents in antitrust case

In defending against federal and state antitrust claims that it monopolized the digital music market, Apple sought to file under seal a variety of information, including its prices, names of other companies, and expert analysis. In a victory for court transparency, the U.S. District Court for the Northern District of California late last week refused, […]

Education companies’ voluntary student-privacy pledge draws mixed reviews

Several education technology companies have signed a pledge to protect student privacy in respects not required by federal law. Reports Politico: Companies signing the pledge — including Microsoft, Amplify, Edmodo, Knewton and Houghton Mifflin Harcourt — will commit to clearly disclose what type of personal information they collect about students, and for what purpose. They […]

Pew study on internet payday lending

As Pew describes it: This report, the fourth in Pew’s Payday Lending in America series, examines Internet-based payday loans and finds that lender practices often have serious detrimental effects on consumers. Online payday loans are more expensive than those offered through stores and are designed to promote renewals and long-term indebtedness, and they frequently result […]

Congressmen Question Huge Jumps in Generic Drug Prices

Blogging for The Wall Street Journal, Ed Silverman reported yesterday: In response to recent reports that the cost of some generic drugs has been unexpectedly rising at a rapid clip, two members of Congress have launched an investigation and asked 14 generic drug makers to providing data about what the lawmakers called the “escalating prices they […]